Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2022

View Archived Issues

Preprints age well, manuscript preprint shows

New DNA intercalator/topo II inhibitor shows improved anticancer activity over doxorubicin

Prodrug form target of JBP-485 and vitamin E developed to treat NASH

GMQ-3 shows promising efficacy in models of lung cancer

Discovery of novel BU-4664L derivatives with potential anticancer activity

Medshine Discovery patents new GLP-1 receptor agonists

Chinese researchers disclose SOS1 inhibitors

Betta Pharmaceuticals divulges new PTPN11 inhibitors

Roche presents compounds for Gram-negative bacterial infections

Mission Therapeutics synthesizes USP30 inhibitors

Novel halogenated phenoxychalcones described with activity in breast cancer cell lines

Siglec-15 promotes osteosarcoma tumor progression

Inhaled remdesivir shows efficacy in nonhuman primate model of SARS-CoV-2 infection

VC-2 vaccine confers protection against viral ocular immunopathogenesis through T-cell infiltration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...